

ongoing trials - trial from www.clinicaltrials.gov

Inhaled dry powder alginate oligosaccharide (OligoG) in cystic fibrosis: sub-group analyses of a double-blind, randomized, placebo-controlled, efficacy and safety trial

Code: CN-XXXXX005 **Year:** 2019 **Date:**

Author: Rye P

Study design (if review, criteria of inclusion for studies)

Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT

Participants

ADULT, OLDER_ADULT

Interventions

DIAGNOSTIC_TEST: :PULMONARY FUNCTION TEST|DIAGNOSTIC_TEST: NASAL ENDOSCOPY| LEUKOSORB FILTER PAPER APPLICATION TO NASAL CAVITY|BEHAVIORAL: SINONASAL OUTCOME TEST 22 QUESTIONNAIRE|CYSTIC FIBROSIS QUESTIONNAIRE-REVISED|BEHAVIORAL: PATIENT HEALTH QUESTIONNAIRE-9|DRUG: STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

Outcome measures

SINONASAL OUTCOME TEST 22 QUESTIONNAIRE|PULMONARY FUNCTION TESTING WILL BE PERFORMED WITH THE FEV1/FVC . 12 weeks|Health Care Utilization, Need for additional doctor visits, antibiotics, oral steroids, 12 weeks|Nasal endoscopy, 12 weeks

See also

Respirology (Carlton, Vic.), 2019, 24, 141â€•

Keywords

non pharmacological intervention - diagn; hydration; Hypertonic Solutions; Inhalation OR nebulised; pharmacological_intervention; Airway clearance drugs -expectorants- mucolytic- mucociliary-; Respiratory System Agents; Bacterial Infections; Isotonic Solutions; Respiratory Tract Infections; Sinusitis; Respiratory Tract Diseases;